Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design (Q28543054)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design	scientific article

Statements

scholarly article

0 references

Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design (English)

0 references

1 reference

based on heuristic

inferred from title

author name string

Yulia Vugmeyster

1

0 references

Cynthia Rohde

2

0 references

Mylene Perreault

3

0 references

Ruth E Gimeno

4

0 references

Pratap Singh

5

0 references

language of work or name

0 references

publication date

2013

1 reference

Monoclonal Antibodies

0 references

5

0 references

3

0 references

373-83

0 references

The storm has cleared: lessons from the CD28 superagonist TGN1412 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169031

29 September 2017

Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169031

29 September 2017

From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169031

29 September 2017

The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169031

29 September 2017

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169031

29 September 2017

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169031

29 September 2017

Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169031

29 September 2017

The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169031

29 September 2017

Interspecies scaling of therapeutic monoclonal antibodies: initial look

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169031

29 September 2017

Target site occupancy: emerging generalizations from clinical and preclinical studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169031

29 September 2017

Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169031

29 September 2017

Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169031

29 September 2017

Appetite enhancement and weight gain by peripheral administration of TrkB agonists in non-human primates.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169031

29 September 2017

Brain-derived neurotrophic factor (BDNF) and food intake regulation: a minireview.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169031

29 September 2017

Target-mediated drug disposition and dynamics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169031

29 September 2017

A novel endocytic recycling signal distinguishes biological responses of Trk neurotrophin receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169031

29 September 2017

Cellular localization of the Trk neurotrophin receptor family in human non-neuronal tissues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169031

29 September 2017

Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169031

29 September 2017

Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169031

3 June 2018

TrkB agonists ameliorate obesity and associated metabolic conditions in mice

1 reference

https://api.crossref.org/works/10.4161%2FMABS.23826

21 January 2018

A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition

1 reference

https://api.crossref.org/works/10.4161%2FMABS.23826

21 January 2018

Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency.

1 reference

https://api.crossref.org/works/10.4161%2FMABS.23826

21 January 2018

Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.

1 reference

https://api.crossref.org/works/10.4161%2FMABS.23826

21 January 2018

Target-mediated drug disposition model for drugs that bind to more than one target

1 reference

https://api.crossref.org/works/10.4161%2FMABS.23826

21 January 2018

Clathrin-dependent endocytosis is required for TrkB-dependent Akt-mediated neuronal protection and dendritic growth.

1 reference

https://api.crossref.org/works/10.4161%2FMABS.23826

21 January 2018

Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

1 reference

https://api.crossref.org/works/10.4161%2FMABS.23826

21 January 2018

Approximations of the target-mediated drug disposition model and identifiability of model parameters.

1 reference

https://api.crossref.org/works/10.4161%2FMABS.23826

21 January 2018

Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms

1 reference

https://pubmed.ncbi.nlm.nih.gov/23529133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23529133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4161/MABS.23826

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28543054&oldid=1418180573"